ArticlebioRxiv : the preprint server for biology2026
Disulfide engineering reveals unexpected pro- and anti-aggregation conformers of human α-synuclein.
Article in bioRxiv : the preprint server for biology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
Abstract
Intrinsically disordered proteins can aggregate in many distinct conformations (polymorphs). Polymorphs are a striking example of fold-switching: one primary structure able to form distinct tertiary structures. Distinct polymorphs can yield distinct molecular, cellular, and disease phenotypes. Disulfide crosslinks canalize disordered proteins into distinct regions of the conformational landscape, even if the monomer remains disordered. Human α-synuclein is a disordered, natively Cys-free protein involved in synaptic transmission. Its amyloid aggregation is implicated in Parkinson's disease and other synucleinopathies. Recent cryo-EM fibril structures have revealed distinct classes of amyloid polymorphs that wild-type human α-synuclein can adopt. We created three double-Cys α-synuclein variants predicted to form intramolecular disulfide bridges compatible with known amyloid polymorphs, plus three other double-Cys variants at arbitrary positions as controls. We purified all six variants as intramolecularly disulfide-crosslinked monomers in solution. Two of the three predicted pro-aggregation variants formed amyloid fibrils as expected, and two of the three control variants did not. Surprisingly, one of the controls formed amyloid fibrils with a distinctive morphology by negative-stain TEM, suggesting the possibility of a previously unknown polymorph. Conversely, the crosslinked variant that failed to aggregate as expected showed sub-stoichiometric, dose-dependent anti-aggregation activity, strongly suppressing amyloid formation by wild-type α-synuclein.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.